- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00820092
Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers
July 29, 2013 updated by: Celtic Pharma Development Services
A Phase 1,Dose Escalation Study to Compare the Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Profiles of the 24-hour Intravenous Administration of Xerecept in Healthy Japanese and Caucasian Adult Volunteers
- To investigate the safety and tolerability of Xerecept during and following a 24-hour intravenous administration to healthy Japanese to healthy Japanese and Caucasian subjects
- To compare the PK profile of hCRF during and following a 24-hour intravenous Xerecept administration between healthy Japanese and Caucasian subjects
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
none needed
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Cypress, California, United States, 90630
- West Coast Clinical Trials
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male and female Japanese subjects who are citizens of Japan
- Healthy male and female Caucasian subjects
- Age range 20-45 years
- BMI >19 and <27 kg/m squared
Exclusion Criteria:
- Female subjects must not be pregnant at the time of study and use adequate birth control methods before,during and 4 weeks after the study
- Subjects must be negative for HCV and HIV
- Subjects must have negative urine tests for drugs of abuse and alcohol at screening
- Subjects must not have any clinically significant medical conditions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Xerecept 1.0
1.0 ug/kg/hr hCRF -24 hour IV infusion
|
24 hour infusion
Other Names:
|
ACTIVE_COMPARATOR: Xerecept 2.0
2.0 ug/kg/hr-24 hour IV infusion
|
24 hour infusion
Other Names:
|
ACTIVE_COMPARATOR: Xerecept 3.0
3.0 ug/kg/hr-24 hour infusion
|
24 hour infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency and severity of AEs Clinical laboratory tests( chemistry,hematology,urinalysis) Physical exam and vital signs ECG AUC, Tmax Cmax Terminal half life AUC for cortisol concentration
Time Frame: 24 hours
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (ACTUAL)
March 1, 2009
Study Completion (ACTUAL)
April 1, 2009
Study Registration Dates
First Submitted
December 14, 2008
First Submitted That Met QC Criteria
January 7, 2009
First Posted (ESTIMATE)
January 9, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
July 30, 2013
Last Update Submitted That Met QC Criteria
July 29, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Xerecept: CPDS 0805
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Edema
-
Eye-yon MedicalCompletedCORNEAL EDEMAIsrael, Poland
-
Federico II UniversityCompletedPseudophakic Cystoid Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
Postgraduate Institute of Medical Education and...CompletedDiabetic Macular Edema | Vision Disorders | Macular Edema, Cystoid | Clinically Significant Macular EdemaIndia
-
National Cardiovascular Center Harapan Kita Hospital...CompletedMyocardial Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
Eye-yon MedicalCompletedChronic Cornel EdemaNetherlands, Israel, Germany, Spain
-
Ellianne M. NasserRecruitingBone Marrow EdemaUnited States
-
University of RochesterNeuroMetrix, Inc.Active, not recruiting
Clinical Trials on Xerecept 1.0
-
PharmaNetCeltic Pharma Development ServicesTerminatedPeritumoral Brain Edema | PRIMARY MALIGNANT and METASTATIC BRAIN TUMORS
-
Forsight Vision4WithdrawnAge-Related Macular DegenerationIsrael
-
Intuitive SurgicalCompleted
-
Karolinska InstitutetCompletedOlder Adults | ParticipationSweden
-
Celtic Pharma Development ServicesNeurobiological TechnologiesCompletedBrain Tumor | Brain EdemaUnited States, Canada
-
Celtic Pharma Development ServicesNeurobiological TechnologiesCompletedBrain Tumor | Brain EdemaUnited States, Canada
-
Menssana Research, Inc.National Heart, Lung, and Blood Institute (NHLBI)UnknownHeart Transplant RejectionUnited States
-
Schweiger Dermatology, PLLCTerminated
-
Celtic Pharma Development ServicesNeurobiological TechnologiesWithdrawnBrain Tumor | Brain EdemaUnited States, Canada
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesChina